Heterogeneous target protein expression in synchronous multiple gastric carcinomas.
To explore the target protein expression in separate tumors in a patient with synchronous multiple gastric carcinomas (SMGCs). Immunohistochemistry for HER2, EGFR, and MET were performed in 282 carcinomas from 141 patients. Of 141 patients with SMGCs, 11.3%, 23.4%, and 14.9% of cases showed HER2, EGFR, and MET protein overexpression, respectively. In SMGC cases with overexpression of target proteins in > 1 tumor, intertumoral heterogeneity was 81.3% (13/16) for HER2, 78.8% (26/33) for EGFR, and 90.5% (19/21) for MET protein. The concordance rate of HER2, EGFR, and MET expression between 2 carcinomas from the same patient was 90.8%, 81.6%, and 86.5%, respectively, with a kappa value below 0.3, indicating slight to fair agreement. We found a considerable intertumoral heterogeneity of target protein overexpression in SMGCs. Our findings support a multicentric origin for SMGC and emphasize the need to perform immunohistochemistry for all synchronous lesions.